V1 sact_regimen
730,471 rows · 12 columns
| MERGED_REGIMEN_ID | MERGED_TUMOUR_ID | HEIGHT_AT_START_OF_REGIMEN | WEIGHT_AT_START_OF_REGIMEN | INTENT_OF_TREATMENT | DATE_DECISION_TO_TREAT | START_DATE_OF_REGIMEN | MAPPED_REGIMEN | CLINICAL_TRIAL | CHEMO_RADIATION | MERGED_PATIENT_ID | BENCHMARK_GROUP |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 220017279 | 220019750 | 1.56 | null | null | null | 2015-01-08 | Dasatinib | N | N | 220029738 | DASATINIB |
| 220017280 | 220007713 | 1.56 | null | Disease modification (D) | 2016-08-13 | 2016-10-24 | ALEMTUZUMAB + FLUDARABINE + MELPHALAN | N | null | 220029739 | ALEMTUZUMAB + FLUDARABINE + MELPHALAN |
| 220017281 | 220007714 | 1.64 | null | Palliative (P) | 2017-11-26 | 2017-12-03 | Dasatinib | N | N | 220029746 | DASATINIB |
| 220017282 | 220014245 | 1.74 | 0 | Curative (C) | 2015-01-08 | 2015-01-08 | Dasatinib | N | N | 220029749 | DASATINIB |
| 220017283 | 220014246 | 1.63 | 57.8 | Curative (C) | 2013-06-06 | 2013-08-20 | Alemtuz+Fludara+Melphalan RIC MUD | N | N | 220029751 | ALEMTUZUMAB + FLUDARABINE + MELPHALAN |
| 220017284 | 220007721 | 1.66 | 79.2 | Curative (C) | 2018-08-20 | 2018-08-31 | ALEMTUZUMAB + FLUDARABINE + MELPHALAN | 01 | null | 220029754 | ALEMTUZUMAB + FLUDARABINE + MELPHALAN |
| 220017285 | 220007721 | 1.52 | null | Curative (C) | 2017-08-06 | 2017-08-07 | Rituximab (Maintenance) | N | N | 220029754 | RITUXIMAB |
| 220017286 | 220007722 | 1.71 | 100 | Curative (C) | 2016-05-11 | 2016-08-16 | AML 18 TRIAL | N | N | 220029756 | AML18 TRIAL |
| 220017287 | 220007724 | 1.68 | null | Curative (C) | null | 2016-01-11 | Rituximab | N | N | 220029760 | RITUXIMAB |
| 220017288 | 220007725 | 1.7 | 85.9 | Curative (C) | 2016-04-27 | 2016-06-05 | AML18 PILOT TRIAL | Y | N | 220029762 | PILOT TRIAL |
| 220017289 | 220007729 | 1.7 | 69.4 | Curative (C) | null | 2015-03-24 | AML18 PILOT TRIAL | null | N | 220029771 | PILOT TRIAL |
| 220017290 | 220007732 | 1.59 | 78 | Curative (C) | 2017-08-22 | 2017-11-26 | AML18 PILOT TRIAL | 01 | N | 220029775 | PILOT TRIAL |
| 220017291 | 220007733 | 1.61 | null | Curative (C) | 2018-12-28 | 2019-01-04 | Dasatinib | 99 | N | 220029778 | DASATINIB |
| 220017292 | 220014256 | 0 | 0 | Curative (C) | 2016-09-08 | 2016-11-05 | Dasatinib | N | N | 220029779 | DASATINIB |
| 220017293 | 220007735 | 1.75 | 84.9 | Disease modification (D) | 2015-01-15 | 2015-01-15 | Rituximab | N | N | 220029786 | RITUXIMAB |
| 220017294 | 220017781 | null | null | Curative (C) | 2013-12-08 | 2013-12-10 | Rituximab | 02 | N | 220029798 | RITUXIMAB |
| 220017295 | 220007739 | null | 81.9 | Disease modification (D) | 2014-01-15 | 2014-01-15 | ALEMTUZUMAB + FLUDARABINE + MELPHALAN | N | N | 220029804 | ALEMTUZUMAB + FLUDARABINE + MELPHALAN |
| 220017296 | 220014261 | 1.55 | 104.8 | Curative (C) | 2015-12-22 | 2016-02-13 | AML 18 TRIAL | null | N | 220029808 | AML18 TRIAL |
| 220017297 | 220007742 | 1.77 | 68.1 | Curative (C) | 2017-11-09 | 2017-11-09 | Dasatinib | N | N | 220029810 | DASATINIB |
| 220017298 | 220007744 | 1.75 | 53.5 | Curative (C) | null | 2016-04-19 | AML18 PILOT TRIAL | N | N | 220029817 | PILOT TRIAL |
| 220017302 | 220007761 | 1.71 | 82.8 | Curative (C) | 2013-06-20 | 2013-08-05 | AML18 PILOT TRIAL | null | null | 220029867 | PILOT TRIAL |
| 220017303 | 220007764 | 1.76 | 0 | Adjuvant (A) | null | 2017-06-13 | Rituximab | 2 | null | 220029884 | RITUXIMAB |
| 220017304 | 220007765 | 1.62 | 76.9 | Disease modification (D) | 2017-05-25 | 2017-09-04 | Dasatinib | N | N | 220029889 | DASATINIB |
| 220017305 | 220007768 | null | null | Disease modification (D) | 2016-02-16 | 2016-02-16 | Dasatinib | 02 | N | 220029890 | DASATINIB |
| 220017306 | 220020894 | null | 70 | Curative (C) | 2018-05-27 | 2018-07-08 | AML18 PILOT TRIAL | 1 | N | 220029900 | PILOT TRIAL |
| 220017307 | 220007769 | 0 | 95.8 | Disease modification (D) | 2017-10-05 | 2018-07-13 | Dasatinib | 99 | N | 220029903 | DASATINIB |
| 220017308 | 220017789 | 1.62 | 80.75 | Disease modification (D) | 2013-11-17 | 2013-11-20 | AML 18 TRIAL | 01 | N | 220029906 | AML18 TRIAL |
| 220017309 | 220007774 | 0 | 49.9 | Disease modification (D) | 2013-10-11 | 2013-12-12 | AML 18 TRIAL | 01 | N | 220029925 | AML18 TRIAL |
| 220017310 | 220007775 | 1.71 | 64.2 | Disease modification (D) | 2017-01-31 | 2017-02-01 | Dasatinib | N | N | 220029931 | DASATINIB |
| 220017311 | 220007775 | 1.63 | 71.4 | Curative (C) | 2018-01-23 | 2018-01-25 | Alemtuz+Fludara+Melphalan RIC MUD | N | N | 220029931 | ALEMTUZUMAB + FLUDARABINE + MELPHALAN |
| 220017312 | 220007777 | 1.62 | 63.1 | Curative (C) | 2014-11-04 | 2014-11-07 | ALEMTUZUMAB + FLUDARABINE + MELPHALAN | N | null | 220029945 | ALEMTUZUMAB + FLUDARABINE + MELPHALAN |
| 220017313 | 220007777 | 1.75 | 71.8 | Curative (C) | 2015-10-29 | 2015-10-29 | AML 18 TRIAL | null | null | 220029945 | AML18 TRIAL |
| 220017314 | 220007778 | null | 102.2 | Curative (C) | null | 2013-10-10 | Dasatinib | N | N | 220029951 | DASATINIB |
| 220017315 | 220007779 | 1.75 | 75 | Curative (C) | 2015-09-06 | 2016-05-09 | Dasatinib | 99 | null | 220029952 | DASATINIB |
| 220017316 | 220007783 | 1.62 | 66 | Curative (C) | null | 2014-08-16 | AML 18 TRIAL | N | N | 220029966 | AML18 TRIAL |
| 220017317 | 220019761 | null | 88.7 | null | null | 2014-05-21 | AML 18 TRIAL | 1 | N | 220029980 | AML18 TRIAL |
| 220017318 | 220007788 | 1.76 | 86 | Curative (C) | 2014-10-15 | 2014-10-16 | AML 18 TRIAL | 01 | null | 220029989 | AML18 TRIAL |
| 220017319 | 220007791 | 1.59 | 56.7 | Disease modification (D) | null | 2018-11-07 | AML 18 TRIAL | 01 | N | 220029990 | AML18 TRIAL |
| 220017320 | 220017797 | null | null | Disease modification (D) | 2015-08-19 | 2015-08-19 | Dasatinib | null | null | 220029995 | DASATINIB |
| 220017321 | 220007794 | null | 80.75 | Palliative (P) | 2017-08-20 | 2017-10-17 | AML 18 TRIAL | N | N | 220030009 | AML18 TRIAL |
| 220017322 | 220007795 | null | 80 | Disease modification (D) | 2017-03-18 | 2017-03-21 | Dasatinib | N | N | 220030022 | DASATINIB |
| 220017324 | 220007798 | 1.7 | 78 | null | 2016-03-25 | 2016-08-17 | Rituximab | N | N | 220030037 | RITUXIMAB |
| 220017325 | 220007801 | 1.9 | null | Curative (C) | 2018-10-21 | 2018-10-21 | Rituximab | N | N | 220030042 | RITUXIMAB |
| 220017326 | 220007803 | 1.59 | 61.6 | Curative (C) | 2017-05-22 | 2017-05-22 | Rituximab | N | N | 220030047 | RITUXIMAB |
| 220017327 | 220007808 | 1.86 | null | Neo-adjuvant (N) | 2016-08-03 | 2016-10-29 | Rituximab | N | N | 220030054 | RITUXIMAB |
| 220017328 | 220007812 | null | 81 | Curative (C) | 2013-09-29 | 2013-11-08 | AML 18 Pilot Trial | N | null | 220030060 | PILOT TRIAL |
| 220017329 | 220007813 | 1.84 | 64.75 | Disease modification (D) | 2014-10-31 | 2014-10-31 | Rituximab | null | N | 220030065 | RITUXIMAB |
| 220017330 | 220014300 | 1.85 | 80.75 | Curative (C) | 2017-12-08 | 2018-01-01 | AML 18 TRIAL | Y | N | 220030066 | AML18 TRIAL |
| 220017331 | 220007817 | 1.56 | 63 | Curative (C) | 2016-01-15 | 2016-01-15 | Alemtuz+Fludara+Melphalan RIC MUD | N | Y | 220030069 | ALEMTUZUMAB + FLUDARABINE + MELPHALAN |
| 220017332 | 220007818 | null | 138.8 | Curative (C) | null | 2016-10-28 | AML 18 TRIAL | Y | null | 220030073 | AML18 TRIAL |